Why the study?
This study investigated the prognostic value of integrating late gadolinium enhancement and left ventricular global longitudinal strain for risk stratification in hypertrophic cardiomyopathy.
Does the integrated use of late gadolinium enhancement (LGE%) on CMR and left ventricular global longitudinal strain (LV-GLS) on echocardiography improve risk stratification for adverse cardiovascular events and sudden cardiac death in patients with hypertrophic cardiomyopathy?
Does the integrated use of late gadolinium enhancement (LGE%) on CMR and left ventricular global longitudinal strain (LV-GLS) on echocardiography improve risk stratification for adverse cardiovascular events and sudden cardiac death in patients with hypertrophic cardiomyopathy?
Integrating CMR-derived late gadolinium enhancement and echocardiographic LV global longitudinal strain provides complementary prognostic value in hypertrophic cardiomyopathy, identifying a high-risk phenotype (LGE >4.2% and LV-GLS <14.3%) with nearly threefold higher risk of cardiovascular events and improved SCD risk reclassification over the ESC risk score alone.
BACKGROUND: Late gadolinium enhancement (LGE) and left ventricular global longitudinal strain (LV-GLS) are structural and functional left ventricular remodeling markers in hypertrophic cardiomyopathy (HCM). OBJECTIVES: This study investigated the prognostic value of integrating both markers for risk stratification in HCM. METHODS: Consecutive patients with HCM who underwent CMR between 2008 and 2020 at 2 tertiary hospitals were retrospectively analyzed. LGE% and LV-GLS were measured, with LV-GLS reported as an absolute value. The primary outcome was cardiovascular (CV) events: CV death, sudden cardiac death-related events, and heart failure hospitalization. RESULTS: Among 652 patients with HCM (median age 56 years; 74% [481 of 652] male), median LGE% and LV-GLS were 4.2% and 14.3%, respectively. During the median 7.4-year follow-up (Q1-Q3: 3.4-10.3 years), 59 patients (9.0%) experienced CV events. Higher LGE% and lower LV-GLS were associated with increased CV events (per 1% LGE% increase, adjusted HR [aHR]: 1.04 [95% CI: 1.01-1.06; P = 0.005]; per 1% LV-GLS decrease, aHR: 1.08 [95% CI 1.00-1.15; P = 0.038]). When analyzing the 4 groups stratified according to LGE% and LV-GLS, patients with both high LGE% (>4.2%) and low LV-GLS (<14.3%) had the highest incidence of CV events (aHR: 2.88; 95% CI: 1.21-6.85; P = 0.017). Mediation analysis showed a significant indirect effect of LGE% on CV events through LV-GLS. Sudden cardiac death-related events were most frequent in patients with both high LGE and low LV-GLS. CONCLUSIONS: LGE and LV-GLS provide complementary prognostic information in HCM. Patients with both increased LGE and decreased LV-GLS are at particularly high risk, highlighting the value of integrating both biomarkers for risk stratification.
No takes yet. Share an insight, caveat, or question.
Kwak et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: